A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select ...
Full year 2026 total revenue of $415 million to $430 million, representing growth of 40% to 45% compared to the midpoint of the full year 2025 guidance range. Positive GAAP operating income for the ...
Full conversion of convertible notes reduces long-term liabilities, removes potential equity overhang, and helps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback